Open AccessChick Embryo Assay as Chemosensitivity Test for Malignant Glioma
Author(s) -
Shoin Katsuo,
Yamashita Junkoh,
Enkaku Fumihide,
Sasaki Takuma,
Tanaka Motohiro,
Yoshio Yoshio
Publication year - 1991
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1991.tb01772.x
Subject(s) - chemosensitivity assay , glioma , chorioallantoic membrane , in vivo , nitrosourea , pathology , embryo , lomustine , medicine , chemotherapy , cancer research , biology , cyclophosphamide , vincristine , microbiology and biotechnology
To predict the efficacy of anticancer drugs such as ACNU [l‐(4‐amino‐2‐methyl‐5‐pyrimidinyl)‐methyl‐3‐(2‐chloroethyl)‐3‐nitrosourea hydrochloride] and MCNU [l‐(2‐chloroethyl)‐3‐(methyl‐α‐D‐glucopyranos‐6‐yl)‐l‐nitrosourea] in the treatment of malignant gliomas, the usefulness of the chick embryo assay as a Chemosensitivity test was studied. Fifty‐seven surgical specimens including benign tumors were examined by this method. All tumor specimens tested could be grafted on the chorioallantoic membrane of chick embryo; the evaluable ratio was 100%. Twenty‐one patients with previously untreated malignant glioma could be evaluated to test the predictability of the clinical effects, judged by computed tomography. There were 7 (78%) instances in which the assay response corresponded to a clinical partial response (true‐positive). There were 2 (22%) false‐positives for the assay, 0 (0%) false‐negative and 12 (100%) true‐negatives. The over‐all predictive accuracy was 90% (19/21). Thus, a high‐degree of positive association exists between the chick embryo assay and the clinical outcome. This in vivo assay system for malignant glioma is advantageous for Chemosensitivity tests because of its convenience, rapidity, and inexpensiveness.